
    
      This study will include 3 parts:

        -  Phase I, Part A: Repeated intra-tumoral (IT) administrations of BT-001 as a single
           agent, in patients with metastatic/advanced solid tumors; dose-escalation will be
           employed.

        -  Phase I, Part B: Repeated IT administrations of BT-001 in combination with intravenous
           (IV) infusions of pembrolizumab in patients with metastatic or advanced solid tumors.

        -  Phase IIa: Repeated IT administrations of BT-001 in combination with IV infusions of
           pembrolizumab in several cohorts of patients with defined metastatic or advanced solid
           tumor conditions.
    
  